摘要
21世纪以来,靶向药物如抗VEGF的人源化单克隆抗体(Bevacizumab,贝伐单抗)和抗EGFR单克隆抗体(人鼠嵌合性单抗Cetuximab,C225,西妥昔单抗和全人源化单抗EGFR抗体,Panitumumab,帕尼单抗)的临床应用,已使复发转移性结直肠癌患者的总生存取得了长足的进步,但临床上应如何更加合理有效地使用这些药物,仍有许多亟待解决的问题。
In the 21stcentury,the integration of Oxaliplatin and Irinotecan as conventional cytotoxic agents, as well as bevacizumab and the epidermal growth factor receptor (EGFR) antibodies, cetuximab and panitumumab, as novel targeted agents into standard medical therapy have greatly improved median overall survival in metastatic CRC.However,how to use targeted drugs more reasonably and properly are still undetermined.
出处
《医学与哲学(B)》
2010年第4期10-12,21,共4页
Medicine & Philosophy(B)
关键词
大肠癌
靶向治疗
进展
colorectal cancer,targeted therapy,progress